Investigating how a protein affects HIV infectivity
Molecular Modeling of the DR domain of an HIV restriction factor PSGL-1
This study is looking at a new protein called PSGL-1 to see how it can help stop HIV from infecting healthy cells, which could lead to new treatments for people living with HIV.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Mason University NIH-funded |
| Lab location | 1 site (Fairfax, United States) |
| Project ID | NIH-11113151 on NIH RePORTER |
What this research studies
This research focuses on understanding how a newly identified protein, PSGL-1, can inhibit the infectivity of HIV. The team will explore the molecular structure of PSGL-1 and its mechanism of action, particularly how it incorporates into HIV particles to prevent them from attaching to and infecting healthy cells. By using advanced modeling techniques, the researchers aim to identify specific features of PSGL-1 that contribute to its anti-HIV properties. This work could lead to the development of new therapeutic strategies for treating HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who may benefit from new therapeutic approaches.
Not a fit: Patients who are not infected with HIV or those who have advanced AIDS may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that enhance the body's ability to fight HIV infection.
How similar studies have performed: Previous research has shown promise in targeting viral mechanisms with similar approaches, indicating potential for success in this area.
Where this research is happening
Fairfax, United States
- George Mason University — Fairfax, United States (Active)
Researchers
- Principal investigator: Wu, Yuntao — George Mason University
- Study coordinator: Wu, Yuntao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.